ePlaza Magazine
Submit news for free

Theravance COPD drug on track for FDA decision by November

The FDA accepted Theravance Biopharma and Mylan’s nebulized chronic obstructive pulmonary disease drug for review, with a PDUFA date of Nov. 13. If cleared, revefenacin would be the first once-daily, nebulized bronchodilator for COPD.

Revefenacin, a nebulized long-acting muscarinic antagonist (LAMA), has had a checkered past—GlaxoSmithKline acquired the rights to revefenacin in 2004 but ditched the candidate after discovering its formulation was incompatible with its proprietary inhaler.

Without missing a beat, Theravance repositioned the drug as a nebulized product and the company now considers this a distinguishing feature.

RELATED: AstraZeneca’s triple-hit COPD inhaler meets goals in phase 3, setting up scrap with GlaxoSmithKline

“Today, patients with moderate to severe COPD do not have access to a nebulized LAMA as a treatment option yet. We believe revefenacin, when approved, represents an important advancement in respiratory care by offering a convenient once-daily option for patients and further strengthens Mylan’s robust and growing respiratory portfolio,” said Mylan President Rajiv Malik, in a statement.

“With positive results in our Phase 3 program, we believe that revefenacin is well positioned to fill this important need,” said Rick Winningham, Theravance CEO. “I commend the team at Theravance Biopharma and Mylan for producing a high-quality submission, and we look forward to working with the FDA in its review of our application.”

In July, the companies reported 12-month safety data from two phase 3 trials that showed revefenacin has a similar safety profile to Boehringer Ingelheim’s Spiriva; the data followed positive efficacy data from a pair of shorter phase 3 studies.

While Theravance and Mylan pitted their drug against Spiriva, Verona Pharma took a complementary approach—in September, the U.K.-based company unveiled phase 2a data that showed combining its RPL554 with Spiriva improved lung function in patients with COPD.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More